TrialDiabetes, obesity & metabolism2022

Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study.

Christof Kazda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.